<DOC>
	<DOCNO>NCT01043029</DOCNO>
	<brief_summary>This multi-center , randomize , double-blind , active control , parallel-group study type 2 diabetes patient moderate renal impairment evaluate effect renal function safety tolerability aleglitazar compare pioglitazone . Patients randomize receive either 150 mcg aleglitazar 45 mg pioglitazone daily oral dos . In addition , diet exercise plan also implement anticipated time study treatment 52 week . The target sample size 200-400 patient .</brief_summary>
	<brief_title>A Study Aleglitazar Type 2 Diabetes Patients With Moderate Renal Impairment</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Pioglitazone</mesh_term>
	<criteria>Adult patient &gt; /= 18 year age Diabetes mellitus , Type 2 Moderately impaired kidney function Drug naive 2 antihyperglycemic medication stable dose 1 month screen BMI 2535 Current previous treatment thiazolidinedione Current previous treatment insulin Treatment fibrates &lt; 3 month prior screen History renal disease diabetic nephropathy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>